Advertisement

The Latest

Crystal Manning-Mitchell, MSN, RN, has been appointed CEO of River Oaks Hospital in Harahan, La., part of King of Prussia, Pa.-based Universal Health Services, according to a LinkedIn post. Ms. Manning-Mitchell began serving in the role in April. Previously, she…

In this episode, Wendy Merchant-Schulte, Vice President of Nursing Services at Orbis, and Dr. Hollie Caldwell, Dean of the College of Nursing at Concordia University, discuss how collaborative academic and healthcare partnerships can create more consistent, student-centered nursing education while…

Orlando, Fla.-based Women’s Center for Radiology is notifying patients of a data breach after unauthorized access to a portion of its computer network exposed personal and protected health information. The imaging provider said it discovered suspicious activity on April 29…

AstraZeneca will pay nearly $34 million to resolve allegations it used illegal kickbacks to influence prescriptions reimbursed by Texas Medicaid. Texas sued AstraZeneca under the Texas Health Care Program Fraud Prevention Act, alleging the drugmaker provided free nursing services and…

AIDS Drug Assistance Program Advocacy and the Partnership for Safe Medicines are urging pharmacies to avoid purchasing discounted HIV medications through online pharmacy-to-pharmacy marketplaces, warning the products may qualify as suspect under FDA guidance and the Drug Supply Chain Security…

The American Association for Cancer Research has called the proposed federal grant regulations published May 29 by the White House’s Office of Management and Budget “reckless” and a “major threat” to the National Institutes of Health.  “The intention of these…

Lacey Crabb, MSN, has been appointed hospital administrator of Ascension Calumet Hospital in Chilton, Wis. Ms. Crabb brings extensive experience in rural healthcare leadership, according to a June 22 Facebook post from the hospital. She will serve as a key…

The New England Journal of Medicine has retracted the clinical trial publication behind Amgen’s rare disease drug Tavneos after two of the study’s authors requested the retraction over undisclosed changes to how patient outcomes were assessed.  In a June 29…

Advertisement